BPC-157 has no human dose. No trial has tested a range of doses in people to find one that works and is safe, which is how a dose is normally set. What exists is a record of what individual studies gave, mostly to rats.
This page lays that record out, so the numbers circulating online can be traced to their source. Nothing here is a dose for anyone to take. What the human studies found is covered in the human evidence for BPC-157, and what they recorded as harm in BPC-157 side effects. BPC-157 sits under the recovery goal as a research-only compound.
Why no dose exists
A drug’s dose normally comes from three steps: toxicity studies in animals, small human studies that raise the dose step by step, and larger trials of the doses that look safe. BPC-157 has not been through the second or third step. A 2025 systematic review found 36 eligible studies, 35 of them preclinical and 1 clinical, and no clinical safety data [3].
The FDA reviewed the first step when BPC-157 came up for compounding in 2026. Its briefing found acute and 28-day toxicity studies only for injection into muscle [1]. It found none by the routes nominated for compounding: by mouth, rectally, under the skin or in the nose.
That gap blocks the usual arithmetic. The FDA wrote that without bioavailability studies for those routes, the no-adverse-effect levels found in rats and dogs cannot be used to estimate safe levels for the routes people actually use [1].
What the animal studies gave
The animal work repeats one dose unit: micrograms, or even nanograms, per kilogram of body weight. In a rat study of a torn muscle-tendon junction, BPC-157 was given at 10 micrograms or 10 nanograms per kilogram into the abdomen, or in drinking water, for up to 42 days [5].
A 2026 rat study of repaired Achilles tendons gave 10 micrograms per kilogram a day into the abdomen for 4 weeks, in groups of 8 rats [6]. The BPC-157 group’s tendon scores were lower, meaning better, but the difference from untreated rats did not reach significance.
The FDA noted a pattern in the gut and liver studies it reviewed. Where two doses were tested, they gave the same effect, so no dose-response relationship could be established [1]. Without one, there is no basis for saying more is better or less is enough.
| Study | Species | Route and amount | Length |
|---|---|---|---|
| Muscle-tendon junction | Rat | 10 µg/kg or 10 ng/kg into the abdomen, or in drinking water | Up to 42 days |
| Achilles tendon repair | Rat | 10 µg/kg a day into the abdomen | 4 weeks |
| Blood-level study | Rat and dog | One dose by vein; also into muscle | Single and repeated doses |
| Bladder pain pilot | Human (12) | 10 mg total, injected into the bladder wall | One procedure |
| Infusion safety pilot | Human (2) | 10 mg by vein, then 20 mg the next day | 2 days |
How long it lasts in the body
The study that traced how BPC-157 moves through the body was in rats and beagle dogs [4]. Its half-life was under 30 minutes, whether given by vein or into muscle. Injected into muscle, 14% to 19% reached the blood in rats and 45% to 51% in dogs.
The peptide was broken into small fragments and then single amino acids. No human results on this have been published, so how long a dose lasts in a human, or how much of it reaches the blood, is not known.
What the three human reports used
All three human reports share a first author, and none had a control group. In 12 women with interstitial cystitis, 10 mg in total was injected around the inflamed bladder wall in a single procedure [8]. In 2 adults, 10 mg was infused by vein on one day and 20 mg the next [9].
The third, a chart review of knee injections, does not state the amount in its abstract [7]. Of 12 patients given BPC-157 alone, 11 reported significant improvement, in a phone survey six months to a year later.
What the registered trials plan
Three registered trials name BPC-157 in their titles. The largest, in 120 adults with hamstring strains, gives a daily injection under the skin or placebo for 14 days [10]. It was recruiting at its last update, and its public record does not list the dose.
An older phase 1 study planned oral tablets, each described as containing 1 mg, in healthy volunteers [11]. Its status is listed as unknown and it has posted no results. A pilot in rotator cuff surgery has not yet begun recruiting [12].
Where it stands with the FDA
BPC-157 appears in none of the three categories of the FDA’s list of bulk substances nominated for compounding, updated May 14, 2026 [13]. The FDA’s own briefing for its July 2026 advisory meeting concluded that the evaluation criteria weigh against listing it [1]. Until a trial reports, the honest answer to the dosage question is that there is not one.
For the peptide most often sold alongside it, see TB-500, and for the one study that gave the two together, see BPC-157 and TB-500 together. For how its legal status works, see are peptides legal.